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Autoimmunity is becoming an increasingly recognized complication in patients
with primary immunodeficiencies (PIDs), including a variety of combined immune
deficiencies such as Recombination Activating Gene (RAG) defects. The approach
to treating autoimmunity in PID patients is complex, requiring a balance between
immunosuppression and susceptibility to infection. Inflammatory arthritis is a feature of
immune dysregulation in many PIDs, and the optimal treatment may differ from first line
therapies that usually consist of disease-modifying anti rheumatic drugs (DMARDs). An
example of mechanism-based therapy of arthritis in PID uses blockade of IL-6 signaling
with tocilizumab for patients with STAT 3 gain-of-function (GOF) mutation and augmented
IL-6 pathway. Herein, we describe two PID cases with arthritis who were found to have
defects in RAG. One patient with refractory inflammatory arthritis experienced remarkable
improvement in symptoms with tocilizumab therapy. Arthritis can be a clinical feature of
immune dysregulation in RAG deficiency, and tocilizumab therapy has been suggested
to have utility in treatment of arthritis in RAG deficiency.
Keywords: recombination activating gene, RAG deficiency, rheumatoid arthritis, primary immunodeficiency,
tocilizumab, refractory arthritis
INTRODUCTION
The co-occurrence of autoimmunity and immunodeficiency was previously thought to be
paradoxical, however, recent understanding of immunology has shed light on common immune
dysregulating mechanisms in both. As these complicated mechanisms are still being elucidated,
treatment strategies for autoimmune conditions are not well-defined in this phenotype. One
of the best studied treatment regiments for autoimmunity is that of rheumatoid arthritis
(RA) in adults and juvenile idiopathic arthritis (JIA) in children. The initial months of
RA are critical for initiation and escalation of therapies as using methotrexate for standard,
first-line monotherapy is sufficient for only one-third of RA patients. For second and
third line therapies, the American College of Rheumatology provides a decision tree that
lists a plethora of biologics for treating RA and JIA with various efficacies and adverse
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event profiles, making selection of the right medication
for specific patients difficult (1, 2). Immune mechanism-
based selection is uncommon in treatment of arthritis in
the general population. However, there is a population of
patients with PIDs where it is imperative to balance the
benefits of immunomodulating therapies with the potential
of increasing susceptibility to infection. By determining the
immune mechanism underlying the patient’s disease, we will be
able to determine personalized targeted therapy.
Inflammatory arthritis in PIDs arises via heterogenous
mechanisms involving immune dysregulation in different
lymphocyte subpopulations. PIDs defined by B-cell pathology are
linked to arthritis: in X-linked agammaglobulinemia (XLA), 7%
of patients had a diagnosis of arthritis, and in common variable
immune deficiency (CVID), 3.2% of patients were diagnosed
with inflammatory arthritis (3, 4). Regulatory T-cell (Treg)
pathology is also linked to arthritis in 3 major cohorts, including
patients with LRBA (31 pts), CTLA4 (133 pts) deficiency, and
STAT3 GOF mutations (13 pts), in which 26, 3, and 26% of
patients had arthritis, respectively (5–7). Inflammatory arthritis
is also associated with other combined immune deficiency (CID)
syndromes. In 55 patients with Wiskott Aldrich syndrome, 29%
experienced arthritis as a complication (8). Arthritis has also been
a known phenomenon in ZAP-70 deficient mouse models of CID
(9). Finally, an association between RAG, themajor player in VDJ
recombination, and arthritis is emerging (10). Patients with RAG
and combined immune deficiency associated with granulomas
and/or autoimmunity (CID-G/A) may present with immune
dysregulation in all ages (11). Chronic refractory arthritis was
part of clinical presentation in a systemic lupus erythematosus
patient with a heterozygous pathogenic RAG mutation and low
RAG function measured by reduced receptor editing (12). To
examine the association between RAG deficiency and arthritis,
we report two RAG-deficient patients with CID that may lay
precedent for further investigation.
CASE REPORT A
Patient A is a 39-year old female from the United Kingdom who
was diagnosed with probable CVID at age 24 after presenting
with recurrent childhood infections, including pneumonias. She
also experienced multiple autoimmune complications, including
vitiligo in her adolescent years and developed alopecia at
age 20 (Figure 1). At age 24, she was hospitalized with
severe bulbar palsy and was diagnosed with myasthenia gravis
without thymoma. At this time, immunological studies were
performed, which were positive for lymphopenia, neutropenia,
autoimmune hemolytic anemia (AIHA), and a IgG deficiency
(3 g/L), but without deficiency in IgM or IgA. Because of
lack of response to two challenges of pneumococcal vaccines,
deficiency in one immunoglobulin isotype, and negative test for
hyper IgM syndrome, a diagnosis of probable CVID was made
(Table 1). She was subsequently started on IVIG replacement,
and azathioprine and pyridostigmine for her myasthenia gravis.
At age 28, she presented with restriction in movement of
joints, prompting synovial fluid analysis which was negative for
inflammatory cells. Subsequently, amuscle biopsy was performed
revealing macrophagic myofasciitis. She initially responded
well to treatment with steroids, but experienced 2 further
relapses of macrophagic myofasciitis over 4 years, requiring
steroids. Methotrexate was started as a steroid-sparing agent and
azathioprine was stopped. She then developed knee arthritis,
and another synovial fluid analysis was done on her right knee,
which demonstrated inflammatory cells. She was diagnosed with
inflammatory arthritis at age 33. She continued on methotrexate
and steroids with addition of sulfasalazine, but due to suboptimal
response, sulfasalazine and methotrexate were replaced with
anti-TNFα with no response, then with anti-IL-1 (Anakinra)
with no significant improvement. At age 34, patient A visited a
rheumatology clinic and was started on tocilizumab, an anti-IL-6
biological agent, resulting in complete remission of joint-related
symptoms. She has been in remission for the past 5 years. As part
of the 2018 BRIDGE study on genetic defects in PID cohorts,
she underwent whole exome sequencing and was found to have
a compound heterozygous RAG2 mutation (c.a. G1352C, b.
T629C; p.a. I210T, b. G451A), causing an average recombination
activity of 6.4 ± 0.2% (11). Elevated IgA reflects inflammation
and patient had progressive B cell loss and very low fraction
of naïve T cells. Anti-cytokine antibodies were also present
(Table 1). Together, based on the immunological phenotype and
reduced recombination activity, CID phenotype was established.
CASE REPORT B
Patient B is a 5 year-old female from Bulgaria who was born full-
term with no complications, but had multiple gastrointestinal
and upper respiratory infections starting at 4 months of age
(Figure 2). She required hospitalization at 14 months for
bacterial gastroenteritis after presenting with high fever, diarrhea,
decreased oral intake, and was subsequently treated with
antibiotics. Two months later, she was hospitalized again with
fever, rash, swelling of the legs, feet, and fingers, with concern
for Kawasaki’s disease after live MMR vaccination. Eventually,
she was diagnosed with macrophage activation syndrome (MAS),
successfully treated with parenteral and oral corticosteroids with
good effect. Given that she was previously hospitalized with a
bacterial infection and recurrent infections since 4 months of
age, she also had a workup for immunodeficiency, which raised
a suspicion for primary immune deficiency (Table 1).
At 20 months of age, she presented with another episode of
fever and swelling of multiple joints with laboratory workup
revealing leukopenia, elevated IgM, elevated CRP, elevated
ESR, elevated ANA titer (1:1,280), and positive anti-dsDNA
and anti-phospholipid IgM antibodies. At this time, she was
diagnosed with inflammatory arthritis, with differential diagnosis
of systemic lupus erythematosus as she fulfilled the WHO
classification criteria for SLE (4/11 criteria: arthritis, leucopenia,
positive ANA and positive dsDNA and APL). Her joint
symptoms were controlled with NSAIDs and glucocorticoids.
At 30 months of age, elevated ANA titers prompted therapy
with hydroxychloroquine and glucocorticoids that resulted in a
reduction in ANA titer to 1:320. Patient B was asymptomatic
until 4 years of age, when she developed alopecia that
was thought to be a side effect of hydroxychloroquine and
therefore discontinued. Approximately 8 months later, she was
hospitalized with pneumonia.
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FIGURE 1 | Summary of Patient A’s clinical history, treatment, and response to therapy. Autoimmune Hemolytic Anemia (AIHA). Combined Immune Deficiency (CID).
Common Variable Immunodeficiency (CVID). Hydroxychloroquine (HCQ).
Because of her clinical history and abnormal immune
phenotype, patient B’s was further investigated. Fortunately, cord
blood was obtained at birth and preserved at the National
Public Cord Blood Bank. Immunological testing of the cord
blood revealed an absence of T cells and B cells, and T-cell
receptor excision circles (TREC) were undetectable. This led her
clinicians to search for SCID-related genetic defects, revealing
a homozygous RAG1 mutation (c. C1443T, p. A444V) which
causes a recombination activity of 1.4± 0.2% (13). Patient B had
low naïve CD4 count, declining B cell numbers, and expansion of
the NK cells. Although patient B had hypergammaglobunemia,
she had a broad autoantibody profile (Table 1). Together, based
on the immunological phenotype and reduced recombination
activity, CID phenotype was established.
DISCUSSION
Patient A and patient B have immunodeficiency, autoimmunity,
and hyperinflammation attributable to RAG deficiency.
Patient A was classified as “probable CVID,” based on
her hypogammaglobulinemia and lack of response to
pneumococcal vaccination. However, she displays a phenotype
characteristic of combined immunodeficiency with granulomas
or autoimmunity (CID-G-AI). In contrast, Patient B has
hypergammaglobulinemia, but nevertheless displays a CID
phenotype based on absent TRECs, low naïve CD4T cell count
and low B cell count (Table 1). Both patients share a history
of arthritis and alopecia, with patient A having additional
complications including cytopenia, myasthenia gravis, and
vitiligo. In CID-G-AI, autoimmune conditions tend to worsen
later in life especially after exposure to environmental triggers
such as viral challenge; this phenomenon may have led to
Kawasaki-like symptoms in patient B after MMR vaccination.
Along this vein, possible exacerbation of Patient B’s currently
moderate symptoms into more severe, treatment-resistant
autoimmune conditions, such as refractory arthritis experienced
by Patient A, is a major concern.
Ultimately, the goal in treating immunodeficient patients is
to perform hematopoietic stem cell transplantation (HSCT) for
immune reconstitution, essentially curing the defect in patient
immune cells. Drugs to treat autoimmune complications often
serve as a bridging therapy to keep the patient as healthy
as possible until eventual transplantation. Our two patients
exemplify the complicated scenarios PID patients encounter
when deciding on which immunomodulating therapies to treat
autoimmune complications. Patient A displayed suboptimal
responses to first line DMARD therapies for arthritis, requiring
a targeted therapy, tocilizumab, to contain her arthritis.
Patient B currently has a milder form of disease and did
not require additional treatment after a short course of
therapy. If Patient B’s disease state worsens, particularly upon
development of inflammatory arthritis that is refractory to first-
line therapy, tocilizumab may be recommended based on her
immune background.
Tocilizumab has been FDA approved for treatment of chronic
inflammatory arthritis in adults (rheumatoid arthritis) and
children (polyarticular juvenile idiopathic arthritis) who fail
classical (synthetic) DMARDs and as first-line biological therapy
for children with systemic subtype of juvenile idiopathic arthritis,
a highly inflammatory disease characterized by high IL-6 blood
levels. Tocilizumab monotherapy was shown to outperform
methotrexate (MTX) as monotherapy in classical DMARD-
naïve RA patients (14, 15). In a network meta-analysis studying
adverse effects of biologics, all biologics including tocilizumab
were associated with significantly higher adverse effects than
MTX, including increased risk of serious infections. Tocilizumab
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TABLE 1 | Immunological phenotype for Patient A and B.
Immune Phenotype Units Patient A Immune Phenotype Units Patient B
RAG Mutation RAG2 RAG Mutation RAG1
Allele a (c.G1352C p.I210T) Allele a and b
Allele b (c.T629C p.G451) (c. C1443T p. A444V)
Relative Recombination
Activity*
% 6.4 ± 2 Relative Recombination
Activity*
% 1.4 ± 0.2
CD3+ Cell/µl 101–667 CD3+ Cell/µl 84–697
CD3+ %Ly 56–66.8 CD3+ %Ly 19–45
CD4+ Cell/µl 54–290 CD4+ Cell/µl 62–254
CD4+ %Ly 43–53.8 CD4+ %Ly 11–19
Naive CD4+CD45RA+ %Ly 5 Naive CD4+CD45RA+ %Ly 3.6–5.8
CD4+CD45RO+ %Ly 95 CD4+CD45RO+ %Ly 94.2
CD4+ CD25+
CD127low
% Ly 4.2 Treg
CD4+CD25+CD127low
%CD4+ 4.0
CD8+ Cell/µl 30–180 CD8+ Cell/µl 18–302
CD8+ %Ly 11.3–17 CD8+ %Ly 4–25
CD56+ Cell/µl 150–244 CD56+ Cell/µl 580
CD56+ %Ly 28.1–36 CD56+ %Ly 50–62
CD19+ Cell/µl 10–50 CD19+ Cell/µl 6
CD19+ %Ly 3.6–7 CD19+ %Ly 0.5 – 9
IgG g/l 467** IgG g/l 1027–1431**
IgA g/l 930 IgA g/l 76.7–103.9
IgM g/l 234 IgM g/l 46.6–77.6
anti–IFNα Yes Anti–IFNα N/A
anti–IFNω No Anti–IFNω N/A
anti–IL−12 Yes Anti–IL−12 N/A
IL−6 pg/ml 22.4 (0–15) IL−6 pg/ml 0 (0–15)
Rheumatological
Phenotype
Units Patient A Rheumatological
Phenotype
Units Patient B
Rheumatoid Factor IU/ml 16 (0–15) TRECs during NBS 0
Anti AchR nmol/L >100nmol/L Anti-dsDNA U/ml 11.4– 37.2 (<20)
positive APA IgM U/ml 15.3 (<10)
Anti-Skeletal Muscle IU/ml 13 (0-55) B2-glycoprotein U/ml 55.7 (<5)
Anti-dsDNA U/ml <1 ANA (1:1280)
Anti-CCPAb negative ESR Elevated
ANA negative C-Reactive Protein Elevated
ENA screen Complement C3 g/l 1.324 (0.75–1.65)
Anti-Skeletal Muscle Complement C4 g/l 0.137 (0.20–.065)
Arthritis Inflammatory Arthritis Juvenille idiopathic
Symmetry Symmetric Symmetry Asymmetric
Joints Involved Knees; no small joints Joints Involved Multiple joints
Erosive Non-erosive Erosive Non-erosive
Values are provided as a range, collected over the course of patient’s clinical history. *Recombination Activity represents values previously reported (11) **IgG level was recorded pre-IVIG
therapy.
conferred equal or less risk for infections when compared to
other biologics such as TNF inhibitors, IL-1 antagonists, or other
mAbs such as rituximab (16). Therefore, among biologicals,
tocilizumab may be a safer and more powerful option for PID
patients who are required to escalate therapy to address refractory
inflammatory arthritis. Its use could be further justified in
patients with PIDs with IL-6 overactivation.
IL-6 overactivation has been previously demonstrated in
the context of five patients with immune dysregulation and
STAT3 gain of function. Consequently, one patient in this
cohort with refractory polyarthritis responded to IL-6 blockade
with tocilizumab (17). As a parallel, partial RAG deficiency
with immune dysregulation may result in treatment refractory
autoimmune disorders such as chronic arthritis. In fact, an
SLE patient with heterozygous RAG mutation and low receptor
editing was reported with refractory arthritis (12). Other
mechanisms of immune dysregulation in RAG deficiency also
overlap with arthritis pathogenesis (18, 19). Abnormal Treg
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FIGURE 2 | Summary of Patient B’s clinical history, arthritis treatment, and response to therapy. Anti-Nuclear Antigens (ANA). Combined Immune Deficiency (CID).
Kawasaki’s Disease (KD). Macrophagic Activation Syndrome (MAS). Non-Steroid Anti-Inflammatory Drug (NSAID). Systemic Lupus Erythematosus (SLE). Upper
Respiratory Infections (URI).
function is a classic finding in autoimmune conditions, and
an abnormal Treg repertoire has been found both in patients
with arthritis and in patients with RAG deficiency. Unlike in
patients with STAT-3 GOF mutation clearly linked to IL-6
pathway overactivation, where IL-6 blockade appears to be a
logical treatment option, choice of treatment in RAG deficiency
is less clear. Although long term effects of IL-6 blockade in
RAG-deficient patients is not yet known, the observation that
refractory inflammatory arthritis in one of these patients was
successfully treated with IL-6 blockade suggests tocilizumab as
a treatment option. In addition, it creates a need to better define
the role of IL-6 pathway in RAG deficiency.
Clinicians taking care of patients with chronic arthritis
should consider exploring for underlying immune deficiency,
such as RAG deficiency, in patients with atypical clinical
presentation, even in the absence of the history of infections.
For example, arthritis in systemic lupus erythematosus is
typically non-erosive and although chronic, usually responds
to treatment (steroids, methotrexate, hydroxychloroquine, etc).
Hence, treatment resistant or erosive arthritis in SLE should
raise a suspicion of underlying immune deficiency. JIA and RA
are not typically associated with specific ANA antibodies (such
as anti-dsDNA, RNP, SSA, SSB etc.). Hence, the presence of
antibodies to specific nuclear antigens in a young child with
chronic inflammatory arthritis should raise a suspicion and
further workup for underlying immune deficiency.
CONCLUDING REMARKS
Two new cases of partial RAG deficiency with multiple
autoimmune complications including arthritis are reported,
one with refractory arthritis successfully treated with anti-IL6
biological agent, tocilizumab. These two cases exemplify the
broad clinical diversity of RAG deficiency, and also serve to
increase awareness of PID background among patients with
refractory arthritis. Better understanding of mechanisms of
immune dysregulation in chronic arthritis will allow targeted
therapies like tocilizumab to be selectively pursued, especially
among vulnerable patients with PID.
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